Retatrutide, a groundbreaking dual-acting glucose-regulated incretin analog, represents a significant progression in peptide treatments for the treatment of type 2 sugar disorders and, increasingly, weight issues. Unlike many existing treatment interventions, retatrutide merges the actions of a GLP-1 receptor stimulant and a GIP receptor activator,